|
...by Chembio using Chembio's patented Dual Path immunoassay test platform (DPP) and will incorporate IDRI's proprietary antigens.
In preliminary studies conducted during the first quarter of 2007, Chembio demonstrated superior analytical sensitivity on certain well-characterized samples from patients with these diseases. These studies resulted in the decision by Chembio and IDRI to enter into two Cooperative Research and Development Agreements to further their joint efforts.
IDRI, which has funding from the National Institutes of Heath and the Bill and Melinda Gates Foundation...
NOTE: All illustrations and photos
have been removed from this article.
More articles from BIOTECH Patent News
Human Genome Sciences and GlaxoSmithKline initiate second phase 3 clin..., May 01, 2007
Martek withdraws original European ARA infant formula patent., May 01, 2007
Oncolytics Biotech announces issuance of 21th United States patent., May 01, 2007
Biomoda files additional patent protection for its lung cancer detecti..., May 01, 2007
NanoLogix files five patents for ultra fast BioNanoChannel diagnostic ..., May 01, 2007
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
